TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04401306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based self-regulated simulation training (SRST)
Description: Participants allocated to the SRST arm train basic laparoscopic skills at home. Participants train by themselves using a portable box training model (BT). Training is conducted and structured through an online application-based training platform. Training is instructed by online instructional videos and texts. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Centralized instructor-regulated simulation training (IRST)
Description: Participants allocated to the IRST arm train basic laparoscopic skills at the simulation centre. Participants train on a portable box training model (BT). Training is structured through an online application-based training platform and facilitated and instructed by surgical specialists. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
Study: NCT05346991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Free Teachers, Tobacco Free Society program
Description: The Tobacco Free Teachers, Tobacco Free Society (TFT-TFS) program provides teachers with the knowledge and skills to quit tobacco use, or to help someone else quit; it also helps schools comply with national tobacco control policies. School principals implement four TFT-TFS program components with teachers in their schools during school hours across an academic year (August-April):~* Adopting a school tobacco control policy~* Providing cessation support (e.g. distribution of self-help quit booklets and referrals to government cessation resources)~* Conducting monthly group discussions with teachers about tobacco~* Hanging six thematic posters in the school~With the goal of establishing a tobacco-free school environment, the program incorporates six program themes: 1. Teachers as Role Models; 2. Health Effects of Tobacco; 3. Motivation to Quit-or Help Others to Quit; 4. Skills to Quit; 5. Dealing with Withdrawal; and 6. Maintenance and Celebration.
Study: NCT02265445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintaining carbapenem therapy
Description: Intravenous therapy, Maintaining carbapenem therapy
Study: NCT03435328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: * Duration of stimulation: 5 minutes.~* Frequency: will be fixed at 50 Hertz.~* Pulse duration: 250 µs.~* Intensity: optimal intensity of TENS (amplitude will be gradually increased to the maximum intensity that the subject will be comfortable and tolerate it).~* Sessions: only one session
Study: NCT00201058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Web-based Asthma Management
Description: Web-based asthma management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic web-based asthma education
Description: 4 computer sessions over a period of 180 days
Study: NCT02704923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Atropine eye drops (1%) administered by sublingual way (2 drops) every 6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops characterized by saline administered by sublingual way (2 drops) every 6 hours
Study: NCT03103672

Intervention type: PROCEDURE
Intervention: Percutaneous transhepatic cholangiography
Description: Percutaneous transhepatic cholangiography (PTC) can be performed via the right midaxillary approach, though a subxiphoid approach is occasionally needed

Intervention type: PROCEDURE
Intervention: Percutaneous transhepatic cholangiography
Description: Percutaneous transhepatic cholangiography (PTC) can be performed via the right midaxillary approach, though a subxiphoid approach is occasionally needed
Study: NCT01777555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02470754

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Cigarette
Description: Usual brand tobacco cigarette smoked by study participant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Cigarette
Description: Usual brand tobacco cigarette smoked by study participant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Cigarette
Description: Usual brand electronic cigarettes smoked by study participant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Cigarette
Description: Usual brand electronic cigarettes smoked by study participant.
Study: NCT03592719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Intervention (MI-PrEP)
Description: The experimental intervention will consist of two sessions. The first session will involve psycho-education on PrEP and Motivational Interviewing to explore ambivalence about PrEP uptake. The second session will involve Motivational Interviewing and case management to explore barriers to accessing PrEP.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual (E-TAU)
Description: Participants assigned to the control condition will receive two sessions, both of which involve psychoeducation on PrEP.
Study: NCT02265419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal treatment with the Cytosorb adsorber
Description: The extracorporeal treatment with the Cytosorb-Adsorber will be started 6 hours after heart surgery operation, the extracorporeal treatment duration will be 24 hours and the observation time 90 days.
Study: NCT02508740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevenopran
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevenopran
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevenopran
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevenopran
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevenopran
Description: Single oral dose
Study: NCT05770115

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl 1
Description: Double layer closure with split thickness with vicryl 1, in continuous, non-locked, 1 cm apart sutures.
Study: NCT01777542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Insulin Growth Factor 1 (rhIGF-1)
Description: Subjects will receive twice daily subcutaneous injections of IGF-1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Human Insulin Growth Factor 1 (rhIGF-1)
Description: Subjects will receive twice daily subcutaneous injections of IGF-1.
Study: NCT05770115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vicryl 2/0
Description: Double layer closure with split thickness with vicryl 2/0, in continuous, non-locked, 1 cm apart sutures.
Study: NCT01777542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive twice daily subcutaneous injections of a saline solution (placebo).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive twice daily subcutaneous injections of a saline solution (placebo).
Study: NCT03143673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACURATE TA™
Description: ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement Surgery.
Study: NCT02362126

Intervention type: DEVICE
Intervention: Endoscopic full thickness resection (EFTR)
Description: Patients undergo EFTR using the FTRD
Study: NCT03379987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PVB morphine
Description: The PVB was performed under ultrasonographic guidance in the sitting position. Surgical disinfection of thoracoabdominal paravertebral area was done. A linear high-frequency transducer (10-12 MHz, Sonosite, Bothell, WA, USA) was used. The scanning process (Longitudinal out-of-plane technique) was started at 5-10 cm lateral to the spinous process of thoracic vertebrae to identify the rounded ribs and parietal pleura underneath. The transducer is then moved progressively more medially until the transverse processes are identified as more squared structure deeper to the ribs. A 100 mm needle was inserted out-of-plane to contact the transverse process of thoracic vertebra and then, walked off above the transverse process 1-1.5 cm deeper searching for loss of resistance injecting 10 ml of 0.25% bupivacaine + 3 mg morphine for group PVB morphine in incremental doses of 3 ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PVB bupivacaine
Description: the same steps mentioned in group PVB morphine but the solution used for paravertebral block contain bupivacaine only 10 ml of 0.25% bupivacaine injected in in incremental doses of 3 ml.
Study: NCT02683486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent oxygen therapy (an auto-titrating oxygen system)
Description: This device is an auto-titrating oxygen system. The system is programmed to maintain a specific target SpO2 by automatically adjusting the oxygen flow rate. The system can deliver flow rates of 0-5 litres/minute.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-term oxygen therapy
Description: This is the patients usual long-term oxygen therapy
Study: NCT03351114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole
Description: Apply Crisaborole 2% ointment to affected skin twice per day.
Study: NCT05245630

Intervention type: PROCEDURE
Intervention: Robotic arm assisted PET/CT guided biopsy
Description: After preparing the participant for the procedure, the participant was positioned on the PET/CT table with the immobilizer.~An automated robotic arm (MAXIO-EX, Perfint healthcare Pvt Ltd, Chennai, India) was used to guide the needle for biopsy.~Co-axial 18 G biopsy needle (BARD Biopsy disposable coaxial biopsy needle pack, Bard Peripheral Vascular, Inc., Arizona, USA) was inserted according to the orientation planned by the robotic biopsy device.~After the location is ensured, the trocar stylet is removed from the coaxial cannula and specimens were retrieved using a semiautomated biopsy gun.~A repeat CT chest was acquired two hours after the procedure to rule out post-procedural complications.~Complications during the procedure were noted, and immediate management was done.

Intervention type: PROCEDURE
Intervention: Robotic arm assisted PET/CT guided biopsy
Description: After preparing the participant for the procedure, the participant was positioned on the PET/CT table with the immobilizer.~An automated robotic arm (MAXIO-EX, Perfint healthcare Pvt Ltd, Chennai, India) was used to guide the needle for biopsy.~Co-axial 18 G biopsy needle (BARD Biopsy disposable coaxial biopsy needle pack, Bard Peripheral Vascular, Inc., Arizona, USA) was inserted according to the orientation planned by the robotic biopsy device.~After the location is ensured, the trocar stylet is removed from the coaxial cannula and specimens were retrieved using a semiautomated biopsy gun.~A repeat CT chest was acquired two hours after the procedure to rule out post-procedural complications.~Complications during the procedure were noted, and immediate management was done.

Intervention type: PROCEDURE
Intervention: PET fused CT-Fluoroscopy guided biopsy
Description: CT fluoroscopy was used to place the biopsy needle to the FDG avid lung lesion
Study: NCT03833752

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Flexible Cystosocpy
Description: Endoscopic Visualization of the Lower Urinary tract using either a flexible cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Rigid Cystoscopy
Description: Endoscopic Visualization of the Lower Urinary tract using either a rigid cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
Study: NCT01942954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile health cognitive stimulation
Study: NCT02455427

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Active tDCS will be applied with the anode positioned over the ipsilesional primary motor cortex and the cathode over the contralateral supraorbital region for 20 minutes (1mA).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy will be administered for 60 minutes

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy will be administered for 60 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: In sham tDCS, no current will be delivered through the tDCS device.
Study: NCT02919748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choral Singing
Description: Weekly sessions at 1 hour of choral singing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Program
Description: Weekly session at 1 hour of health education talk and group activities
Study: NCT01030315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10760A or placebo
Description: Once, 0.04 mcg/kg to 2.0mcg/kg once intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10760A or placebo
Description: Once, 0.04 mcg/kg to 2.0mcg/kg once intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10760A or placebo
Description: Once, 0.04 mcg/kg to 2.0mcg/kg once intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10760A or placebo
Description: Once, 0.04 mcg/kg to 2.0mcg/kg once intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10760A or placebo
Description: Once, 0.04 mcg/kg to 2.0mcg/kg once intravenously
Study: NCT02359929

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stromal cells (MSCs)
Description: Infusion of MSCs delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 1000000 cells/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stromal cells (MSCs)
Description: Infusion of MSCs delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 1000000 cells/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stromal cells (MSCs)
Description: Infusion of MSCs delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 1000000 cells/kg.
Study: NCT03637036

Intervention type: OTHER
Group type: OTHER
Intervention: Communication intervention
Description: The intervention is a communication inviting staff to take up the influenza vaccination. Different versions of the communication are created, and the investigators will compare uptake rates between staff that received different letters.

Intervention type: OTHER
Group type: OTHER
Intervention: Communication intervention
Description: The intervention is a communication inviting staff to take up the influenza vaccination. Different versions of the communication are created, and the investigators will compare uptake rates between staff that received different letters.

Intervention type: OTHER
Group type: OTHER
Intervention: Communication intervention
Description: The intervention is a communication inviting staff to take up the influenza vaccination. Different versions of the communication are created, and the investigators will compare uptake rates between staff that received different letters.
Study: NCT05245630

Intervention type: PROCEDURE
Intervention: PET fused CT-Fluoroscopy guided biopsy
Description: CT fluoroscopy was used to place the biopsy needle to the FDG avid lung lesion
Study: NCT00987896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colonoscopy with Megachannel™ device loaded
Description: Before colonoscopy, megachannel is loaded on the endoscope, during colonoscopy megachannel will be inserted into the patient via the endoscope placed in the colon
Study: NCT04779294

Intervention type: DIAGNOSTIC_TEST
Intervention: STAN ( St wave analysis) and fetal blood sample-lactate
Description: The CTG will be analysed by an expert group additional to the standard procedure that have been done in Labour already. The STAN analysis will be decrypted/ demasked anonymously by the Company producing these machines.
Study: NCT03112525

Intervention type: DIAGNOSTIC_TEST
Intervention: CYP3A4/5 and P-gp phenotyping
Description: Phenotyping using a simplified version of the Geneva cocktail

Intervention type: DIAGNOSTIC_TEST
Intervention: CYP3A4/5 and P-gp phenotyping
Description: Phenotyping using a simplified version of the Geneva cocktail

Intervention type: GENETIC
Intervention: CYP3A4/5 and P-gp genotyping
Description: Selected CYP3A4, CYP3A5, CYP3A7 and ABCB1 single nucleotide polymorphism (SNP) determination

Intervention type: GENETIC
Intervention: CYP3A4/5 and P-gp genotyping
Description: Selected CYP3A4, CYP3A5, CYP3A7 and ABCB1 single nucleotide polymorphism (SNP) determination
Study: NCT00334581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Administration throughout the study period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Administration throughout the study period
Study: NCT01229943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate
Description: Given IM
Study: NCT00545532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir
Description: Dose ranging between 30 to 150 mg orally administered as syrup or capsules (depending on participant's age and weight) po twice daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir
Description: Dose ranging between 30 to 150 mg orally administered as syrup or capsules (depending on participant's age and weight) po twice daily for 10 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo matched to oseltamivir po twice daily for 10 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo matched to oseltamivir po twice daily for 10 days
Study: NCT00105833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care - Depression Decision Support (DDS)
Description: Multifaceted collaborative intervention for depression based in primary care
Study: NCT03505489

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep inhalation technique
Description: Use of deep inhalations for administration of inhalant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep inhalation technique
Description: Use of deep inhalations for administration of inhalant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tidal breathing technique
Description: Use of tidal breathing for administration of inhalant
Study: NCT04202055

Intervention type: OTHER
Intervention: Biomarker analysis
Description: Detection of biomarker in cerebrospinal fluid
Study: NCT03505489

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tidal breathing technique
Description: Use of tidal breathing for administration of inhalant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine
Description: Methacholine direct bronchoconstrictor used for bronchoprovocation challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine
Description: Methacholine direct bronchoconstrictor used for bronchoprovocation challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Mannitol indirect bronchoconstrictor used for bronchoprovocation challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Mannitol indirect bronchoconstrictor used for bronchoprovocation challenge
Study: NCT04547114

Intervention type: DIAGNOSTIC_TEST
Intervention: Multicapillary column coupled ion mobility spectrometry
Description: sampling of nasal air via a foam cuffed oxygen catheter

Intervention type: DIAGNOSTIC_TEST
Intervention: Multicapillary column coupled ion mobility spectrometry
Description: sampling of nasal air via a foam cuffed oxygen catheter
Study: NCT01149486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan potassium/Hydrochlorothiazide
Description: 100/25 mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyzaar®
Description: 100/25 mg Tablets
Study: NCT06136286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) Cuff
Description: The intervention group will receive therapy with a blood flow restriction cuff that restricts blood flow at their individual limb occlusion pressure during specific exercises.
Study: NCT00538486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan plus Metformin
Description: Telmisartan 80mg 1/d, Metformin 250mg 2/d